ArticleCancers2025
Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.
Chris Ho-Ming Wong, Jamie Tsun Chiu, Ivan Ching-Ho Ko, David Ka-Wai Leung, Brian Siu, Cheuk-Kin Kevin Cheng, Yung-Yung Joycelyn Lim, Hiu Tung Mok, Chun-Fai Brian Kwok, Cheuk Yi Tang and 5 more
Abstract read
In one paragraphArticle in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Chris Ho-Ming WongSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Jamie Tsun ChiuSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ivan Ching-Ho KoSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
David Ka-Wai LeungSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-2078-7934 Brian SiuSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Cheuk-Kin Kevin ChengSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-3294-8790 Yung-Yung Joycelyn LimSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Hiu Tung MokSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chun-Fai Brian KwokSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Cheuk Yi TangSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Steven Chi-Ho LeungSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-5484-9390 Kang LiuSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-7929-6534 Peter Ka-Fung ChiuSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-1499-8372 Jeremy Yuen-Chun TeohSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-9361-2342 Chi Fai NgSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-1723-9646 Funding
Asia Prostate Cancer (A-Cap) study support fund. nilTakeda Pharmaceuticals (Hong Kong) Limited (IISR-2023-200391; X99034)
6 · The paper itselfAbstract
Prostate cancer is the second most commonly found malignancy for men worldwide, with its prevalence increasing with age [...].
Indexed as
androgen deprivation therapy (ADT)docetaxeldrug–drug interactionmetastatic hormone-sensitive prostate cancer (mHSPC)prostate cancerproton-pump inhibitor (PPI)
Identifiers
PMID40940975
PMCPMC12427316
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390